1Hansson L. The Hypertension Optimal Treatment sdudy and the importance of lowering blood pressure. J Hypertens Suppl 1999 Fet; 17(1): S9～13.
2Forette F, Seux ML, Staessen JA, et al. Gil Extremera B Prevention of dementia in radnomised double- blind placebocontrolled Systolic Hypertension in Europe ( Syst - Eur) trial.Lancet 1998 Oct;352(9137) :1347.
3Hansson L and Hedner T. Lindholm LThe Captopril Prevention Project(CAPPP) in hypertension - baseline data and current status. SO-Blood Press 1997 Nov;6(6):365.
4Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin - converting- enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial Lancet 1999 Feb;353(9153):611.
5Alexander LM. Guidelines for hypertension treatment: applicatious for prokmary case practice - areview of the JNC VI report. SO- Lippincotts Prim Care Pract 1998 Sep;2(5):485.
6Hall WD. Risk reduction associated with lwoering systolic blood pressure: review of clinical trial data. Am Heart J 1999 Sep; 138(3 Pt 2) :225.
7Psaty BM, Furberg CD. Clinical implications of the World Health Organization - International Society of Hypertension statement on calcium antagonists. J Hypertens 1997 Nov;15(11):1197.
8Hansson L, Hedner T, Himmelmann A. The 1999 WHO -ISH Guidelines for the Management of Hypertensin - new targets, new treatment and a comperhensive approach to total cardiovascular risk reduction. Blood Press Suppl 1999; 1 ( 1 ): 3.
9Sato A, Suzuki Y, Saruta T. Effects of spironolactne and angiotensin- converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension. Hypertens Res 1999;22(1) :17.
